EGFR and sarcomatoid carcinoma: In EGFR-mutated ADCs, the co-occurrence of TP53 pathogenic alterations has been reported to increase the risk of histological changes not only in SCLC transformation but also in SCC, sarcomatoid carcinoma and LCNET [30,37,40].